Literature DB >> 7083173

Mechanism of interaction of CC-1065 (NSC 298223) with DNA.

D H Swenson, L H Li, L H Hurley, J S Rokem, G L Petzold, B D Dayton, T L Wallace, A H Lin, W C Krueger.   

Abstract

CC-1065 (NSC 298223), a potent new antitumor antibiotic produced by Streptomyces zelensis, interacts strongly with double-stranded DNA and appears to exert its cytotoxic effects through disruption of DNA synthesis. We undertook this study to elucidate the sites and mechanisms of CC-1065 interaction with DNA. The binding of CC-1065 to synthetic and native DNA was examined by differential circular dichroism or by Sephadex chromatography with photometric detection. The binding of CC-1065 with calf thymus DNA was rapid, being complete within 2 hr, and saturated at 1 drug per 7 to 11 base pairs. The interaction of CC-1065 with synthetic DNA polymers indicated a specificity for adenine- and thymine-rich sites. Agarose gel electrophoresis of CC-1065-treated supercoiled DNA showed that CC-1065 did not intercalate. Site exclusion studies using substitutions in the DNA grooves showed CC-1065 to bind primarily in the minor groove. CC-1065 did not cause DNA breaks; it inhibited susceptibility of DNA to nuclease S1 digestion. It raised the thermal melting temperature of DNA, and it inhibited the ethidium-induced unwinding of DNA. Thus, in contrast to many antitumor agents, CC-1065 stabilized the DNA helix. DNA helix overstabilization may be relevant to the mechanism of action of CC-1065.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083173

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Ramos; D Donato
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Hightower; R Ramos; D Donato; M Penalver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Theoretical study of the sequence specificity in the covalent binding of the antitumor drug CC-1065 to DNA.

Authors:  K Zakrzewska; M Randrianarivelo; B Pullman
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

4.  Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.

Authors:  Mark S Tichenor; John D Trzupek; David B Kastrinsky; Futoshi Shiga; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2006-12-13       Impact factor: 15.419

5.  Multiple Rad5 activities mediate sister chromatid recombination to bypass DNA damage at stalled replication forks.

Authors:  Eugen C Minca; David Kowalski
Journal:  Mol Cell       Date:  2010-06-11       Impact factor: 17.970

6.  Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex.

Authors:  D R Needham-VanDevanter; L H Hurley; V L Reynolds; N Y Theriault; W C Krueger; W Wierenga
Journal:  Nucleic Acids Res       Date:  1984-08-10       Impact factor: 16.971

7.  Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.

Authors:  B J Foster; P M LoRusso; E Poplin; M Zalupski; M Valdivieso; A Wozniak; L Flaherty; D A Kasunic; R H Earhart; L H Baker
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065.

Authors:  L H Li; R C Kelly; M A Warpehoski; J P McGovren; I Gebhard; T F DeKoning
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

9.  V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.

Authors:  R K Butryn; K S Smith; E G Adams; I Abraham; J Stackpole; K E Sampson; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.

Authors:  B K Bhuyan; K S Smith; E G Adams; T L Wallace; D D Von Hoff; L H Li
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.